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Abstract  
 
Aim To explore participants’ experiences of intensifying insulin therapy during 
the Treating to Target in Type 2 Diabetes (4-T) trial. 
Methods In-depth interviews were conducted with 41 trial participants who 
had had their insulin therapy intensified during 4-T.  Data were analysed using 
an inductive, thematic approach. 
Results The vast majority of participants were receptive towards intensifying 
treatment.  Whilst some were happy simply to follow health professionals’ 
recommendations, others saw taking two types of insulin as a more effective 
way of controlling their diabetes.  Post-intensification, participants sought to 
remember to take their additional injections by developing injection related 
strategies and daily routines.  The need to inject insulin whilst in public often 
arose more frequently following intensification and was a consistent source of 
anxiety.  Those who were worried about injecting in public sought to avoid 
having to do so; for example, by injecting in toilets or by advancing or delaying 
the timing of their injections. 
Conclusions It was not increasing the number of daily injections per se which 
was problematic for 4-T participants who had agreed to have their insulin 
therapies intensified, but the increased likelihood of having to inject insulin in 
public.  Addressing concerns about injecting in public places may help 
promote adherence to intensified insulin regimens. 
 
Keywords: intensive therapy; adherence; patient experience; qualitative 
methods 
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Introduction 
 
Achieving optimal levels of glycated haemoglobin (HbA1c) requires control of 
both fasting blood glucose (FBG) and post-prandial blood glucose (PPBG). As 
endogenous meal-related insulin secretion declines, people with type 2 
diabetes who are treated with long-acting insulin require the addition of rapid-
acting insulin to improve glycaemic control, a process termed intensification of 
insulin therapy [1]. 
 
Whilst the intensification of insulin therapy is an important stage in the 
treatment process, the vast majority of research has focused on barriers to 
initiating insulin [1].  Several studies have highlighted that individuals may 
seek to avoid initiating insulin due, for example, to the perceived pain of 
injecting, the inconvenience of having to administer daily injections, and the 
belief that insulin signifies personal failure to self-manage their disease 
effectively [2, 3, 4, 5].  Few studies have sought to explore whether similar 
barriers exist when intensifying insulin therapies [1, 6, 7]. 
 
Elsewhere, we have described attitudes towards initiating insulin which were 
held by participants in the Treating to Target in Type 2 Diabetes (4-T) trial [8].  
Here, we explore trial participants’ accounts of having had their insulin 
therapies intensified during 4-T. 
  
The 4-T trial 
The 4-T trial was a large, three-year, multi-centre, open label trial conducted 
to compare the efficacy of three different insulin regimens when added to oral 
hypoglycaemic agents (OHA) in people with type 2 diabetes [9, 10].  The trial 
evaluated the impact of basal (insulin detemir), prandial (insulin aspart) and 
biphasic (insulin aspart 30) based insulin regimens in participants 
inadequately controlled on metformin and/or sulfonylurea therapy.  The trial 
employed a treat-to-target approach (HbA1c  6.5 %).  In order to inform 
adjustments to daily insulin doses, participants were required to undertake 
regular self-monitoring of blood glucose (SMBG) and to provide trial staff with 
SMBG readings.  Participants not achieving target glycaemic control in years 
two and three of 4-T had their sulfonylurea (if taken) discontinued (metformin, 
if taken, was continued) and a second insulin formulation added [Fig 1]. 
 
4-T data show that at the end of the first year of the trial, less than a quarter of 
all participants achieved target glycaemic control (biphasic 17%, prandial 
24%, basal 8%).  At the end of the trial, less than half achieved target 
glycaemic control (biphasic 32%, prandial 45%, basal 43%) [9, 10].  This 
interview study was undertaken to understand why the majority of participants 
did not achieve the glycaemic target.  A key objective was to explore their 
views about having their insulin therapies intensified, their experiences of 
taking two types of insulin daily, and whether experiences of intensification 
impacted upon their perceived commitment and ability to adhere to their 
treatment regimens. 
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Methods 
 
Qualitative approaches are recommended when little is known in advance 
about the area of investigation [11, 12].  In this study, we utilized single, in-
depth interviews as these encourage participants to display their own 
understandings and meanings and permit (unanticipated) themes and 
hypotheses to be identified and explored [13].  The research was approved by 
the Hertfordshire Research Ethics Committee (ref: 08/H0311/98). 
 
Sampling 
Our sampling and recruitment methods have been reported elsewhere [8].  In 
brief, 11 of the 58 4-T centres were included in the study, which were selected 
to ensure diversity in centre size, geographical location and research profile. 
Trial participants were recruited using an opt-in procedure. To aid sampling, 
those who opted-in also permitted the research team to access their trial data.  
As the number of participants who opted-in to the study (n=68) was greater 
than that required to meet the study’s sample size (n=45), purposive selection 
was used to recruit a final sample which included equal numbers from across 
the three treatment arms and which broadly reflected the wider trial population 
in terms of age, gender and variation in glycaemic control. 
 
Data collection & analysis 
Interviews were informed by a topic guide and conducted at a time and 
location convenient to participants.  Interviews were conducted by a non-
clinical researcher (NJ), lasted between 40 minutes and 2 hours, were tape 
recorded, and explored participants’ experiences of taking part in and 
receiving care during 4-T (including their encounters with health 
professionals); their views and perceptions of insulin; their experiences of 
intensification and associated self-management practices; their reasons for 
adhering and not-adhering to insulin therapies (both pre and post 
intensification); and strategies for incorporating intensified insulin regimens 
into daily life. 
 
The study was informed by the principles of grounded theory which involves 
concurrent data collection and analysis, together with efforts to check and 
refine developing categories of data by using the method of constant 
comparison.  This method involves systematically comparing interview 
transcripts in order to identify cross-cutting themes and common experiences 
[13].  Themes and hypotheses identified in early interviews informed questions 
in later interviews. Team members independently reviewed data and regular 
meetings were held during and after data collection to explore participants’ 
underlying reasoning, discuss deviant cases and reach agreement on 
recurrent themes and findings. QSR NVivo 2, a qualitative data-indexing 
package, was used to code the data. Interviews were coded to capture data 
relating to the areas explored in the topic guides as well as emerging findings. 
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Results 
 
Participants were broadly representative of the 4-T trial population in relation 
to age, gender and glycaemic control, and included those with both high and 
low final HbA1c results  (range: 5.3 – 9.9%) [Table 1].  Out of the 45 4-T 
participants who took part in the study, 41 (91%) reported having had their 
insulin therapy intensified during the trial [Fig 1].  We draw upon these 41 
participants’ accounts in the remainder of this paper.  
 
Receptiveness towards intensification 
The vast majority of participants appeared to have been ‘psychologically 
receptive’ [8] towards intensifying their insulin therapies.  The reasons 
participants gave for agreeing to intensify treatment broadly fell into one of 
two categories: ‘doctor knows best’ and ‘to aid control’.  Participants who 
appeared happy to follow health professionals’ recommendations often 
seemed unsure, precisely, why the second insulin was being added, but felt 
that ‘I'm no expert so if they told me I needed it then I accepted their word’ 
(Pt24).  In contrast, those who appeared to believe that intensification would 
aid control, tended to see the role of the additional insulin they had been 
asked to take as helping to either top-up or balance out the insulin they were 
already taking. 
 
‘Topping up’ explanations appeared to be rooted in participants’ experiences 
of undertaking SMBG during the trial and discussing their readings with 4-T 
staff.  As a result of undertaking SMBG, some participants reported being able 
to observe how their blood sugar levels were either ‘terrible in the morning’ 
(Pt7) or ‘going up in the evening’ (Pt30), which in turn enabled them to see 
taking two types of insulin as a means to achieve consistent readings over a 
24 hour period (Pt45, Box 1).  Those participants who welcomed 
intensification as a means of ‘balancing out’ their insulin reported having 
become concerned that the doses of their initial insulin were too high.  In this 
context, introducing a second type of insulin was perceived as a means of 
enabling doses of their initial insulin to be reduced to within more ‘acceptable’ 
limits (Pt13, Box 1). 
 
Managing two types of insulin 
In the majority of cases, participants appeared to have adapted effectively to 
managing their intensified insulin regimen.  This is because, from early on in 
the trial, participants had usually established practices and routines which 
helped them to remember to administer their daily injections.  Practices 
included: carrying insulin pens around in pockets and bags, keeping basal 
insulin next to the bed or prandial insulin in the kitchen, and receiving 
reminders to inject from friends and family members.  These strategies served 
to make having to take insulin part of everyday life, ‘like cleaning your teeth’ 
(Pt37). 
 
Intensification could result in participants having to develop and adapt their 
routines.  Participants randomised to prandial insulin, for example, 
occasionally reported difficulties remembering to take their new (basal) insulin 
at a set time each night, as they were used to injecting insulin with meals 
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(Pt36, Box 1).  However, increasing the frequency of daily injections tended 
not to be seen as problematic by these participants because, as patient Pt39 
explained, ‘I was already injecting three times a day […] once more wasn’t 
going to make any difference.’ 
 
For participants randomized to basal insulin, having their treatment intensified 
meant going from one or two daily injections of insulin to having to inject up to 
five times a day.  This news was sometimes met with surprise and 
apprehension amongst participants who were unsure how they were going to 
fit the additional injections into their daily lives (Pt28, Box 1).  As a result, their 
new injection regimen could require participants to make conscious and 
deliberate efforts to adapt daily practices, where ‘You have to just think 
through the logistics; a little bit of when and where you take your medication’ 
(Pt33). However, as participant Pt11 (Box 1) highlights, increasing the number 
of daily injections from once/twice to four/five times a day could help make 
injecting more routine and therefore a more normal aspect of everyday life. 
 
Difficulties with injecting in public 
Whilst the majority of participants had adjusted to intensification by adopting 
strategies which helped them to remember to take their injections, most 
disliked having to inject in public.  All participants who had had their insulin 
therapies intensified were required to administer at least one daily injection of 
insulin with meals (Fig 1) and participants described mealtimes as occasions 
when they were most likely to have to inject outside their homes.  Fear of 
others’ (negative) reactions, such as putting them off their dinner (Pt42, Box 
1) or being seen as either ‘unclean’ or a ‘drug addict’ (Pt31, Box 1) resulted in 
participants trying to avoid having to inject in restaurants and cafes.  When 
dining out, therefore, participants frequently injected in the toilet (Pt26, Box 1).  
Toilets, however, were not always seen as ideal (or hygienic) places in which 
to inject (Pt1, Box 1).  Hence participants who wished to avoid injecting in the 
toilet or at the table, described how they would take their insulin up to thirty 
minutes before or after their meal so that they could inject in the car en-route 
to the restaurant, or upon arriving home (Pt21, Box 1).  These participants 
tended to see advancing or delaying mealtime insulin injections as falling 
within treatment parameters and thus saw themselves as adherent.  Rather 
than alter the timing of their injections, other participants developed alternative 
strategies, such as avoiding eating out (Pt23, Box 1). 
 
Discussion 
 
Although it is often assumed that people with type 2 diabetes may be 
psychologically resistant to intensifying insulin therapy [1] we found that the 
majority of 4-T participants were willing to use an additional type of insulin.  
Their experiences of intensification suggest that it is not the increased 
frequency of injections per se which participants found most problematic, but 
rather the increased likelihood of having to inject insulin in public and, 
potentially, experience negative reactions from others.  
 
The vast majority of participants were ‘psychologically receptive’ [8] towards 
the intensification of their insulin therapies.  Deference to health professionals’ 
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expertise, the potential to record more consistent SMBG readings, and to 
achieve reductions in doses of initial insulin post-intensification were all 
important factors promoting acceptance towards taking two types of insulin.  
Previous research has shown that patients may not always desire to be highly 
involved in making decisions about treatment and may instead prefer to defer 
such decisions to health professionals [14].  Whilst there is currently a dearth 
of qualitative studies that explore experiences of taking insulin amongst 
people with type 2 diabetes, research has shown that individuals may be keen 
to limit the amount of insulin they inject on a daily basis [15]. 
 
Making injections part of daily routines helped 4-T participants remember to 
take their different types of insulin at appropriate times of the day.  This 
finding is consistent with previous research, which found that cultivating 
routines could help individuals with type 2 diabetes remember to take their 
OHA [16].  Qualitative studies of patient adherence to medications for other 
forms of chronic illness, such as epilepsy, have reported similar findings [17]. 
 
Whilst participants were willing to increase the number of daily injections, 
many were worried about taking their insulin in public, due to the stigma which 
they associated with injecting and their fears about how other people may 
react. In this context, the requirement to inject insulin with meals created 
difficulties for participants when eating out.  Most reported trying to find ways 
of avoiding having to inject in front of others; for example, by injecting in toilets 
or by advancing or delaying the timing of their injections.  
 
The potential for injections to induce feelings of social embarrassment is a 
recognised feature of ‘psychological insulin resistance’ [18].  Whilst we argue 
that the majority of our participants were receptive towards taking insulin, the 
fact that feelings of stigma appeared to lead some to advance the timing of 
their mealtime insulin injections is worrying, as this can increase the risk of 
hypoglycaemia, especially amongst those with tight glycaemic control.  
Similarly, delaying mealtime insulin injections can result in surges in post-
prandial blood glucose levels and a rise in overall HbA1c.   
 
Sub-optimal injecting practices (such as injecting in toilets and altering the 
timing of injections) have been reported in other qualitative studies involving 
people with type 1 and type 2 diabetes [19].  Our findings highlight that whilst 
4-T participants reported engaging in these practices they appeared not to 
view their actions as signs of treatment non-adherence.  This finding is 
important, as it suggests individuals with type 2 diabetes may view feelings of 
stigma as personal difficulties, as opposed to treatment barriers which could, 
or should, be shared with health professionals. 
 
Practice implications 
Health professionals need to remember that some individuals with type 2 
diabetes may be worried about injecting insulin in public.  Concerns about 
injecting insulin in public should be fully addressed by health professionals.  
Individuals should be given clear and consistent advice regarding when to 
administer their injections and both patients and health professionals should 
work together to identify practical strategies for alleviating concerns about 
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injecting in public.  Health professionals could also work with individuals who 
have type 2 diabetes, to identify and cultivate daily medication routines which 
may foster adherence to insulin therapies. 
 
Whilst the role of SMBG in the care of individuals with type 2 diabetes is 
controversial, given the lack of evidence that it leads to clinical improvements 
[20], our findings suggest that encouraging SMBG at the point where 
intensification may shortly be needed could help foster receptiveness towards 
taking two types of insulin.  Prior to intensification, individuals with type 2 
diabetes could be supported to take regular SMBG readings over the course 
of the day, and encouraged to discuss the results with their designated health 
professionals.  Drawing attention to high SMBG readings may help individuals 
in coming to view intensified insulin regimens as potentially offering a more 
effective approach to controlling their diabetes. 
 
Strengths and limitations 
This study provides an in-depth perspective on 4-T participants’ experiences 
of intensifying three different insulin regimens, this being a highly under 
explored area. It is limited insofar as it is United Kingdom based, and the vast 
majority of interviewees were White-British, thus restricting the extent to which 
findings may be transferred to other health care systems and ethnic groups. 
By virtue of having agreed to take part in 4-T, participants may have held 
more positive views and beliefs about insulin than the wider population of 
people with type 2 diabetes.  Finally, participants’ retrospective accounts may 
be subject to recall bias, although it must be noted that purposive sampling 
meant the study included trial participants with high and low final HbA1c 
results.  Further research could usefully explore understandings and 
experiences of intensifying insulin therapies amongst individuals with type 2 
diabetes receiving treatment in non-trial settings. 
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Notes 
* Twice a day if required 
** One participant not intensified due to having achieved trial target 
*** One participant not intensified due to having achieved trial target.  One participant not intensified as not 
considered clinically appropriate 
**** One participant not intensified due to having achieved trial target 
 
PRANDIAL 
INSULIN TAKEN 
AT LUNCHTIME 
(MIDDAY) 
68 4-T PARTICIPANTS OPTED-IN 
45 4-T PARTICIPANTS 
PURPOSEFULLY 
SAMPLED 
Figure 1 Initial and intensified insulin regimens for 4-T participants 
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Table 1 Participant characteristics 
 
   
Participants 4-T 
(n=708) 
Qualitative 
sample 
(n=45) 
Age   
Mean age ( SD) 61.7 (9.8)* 64.7 ( 8.5) † 
Sex   
Male (%) 454 (64) 29 (64) 
Female (%) 254 (36) 16 (36) 
   
Randomisation   
Biphasic (%) 235 (33) 15 (33) 
Prandial (%) 239 (34) 15 (33) 
Basal (%) 234 (33) 15 (33) 
   
Glycated hemoglobin at Yr 3   
Median HbA1c 6.9% 6.9% 
Number (%) of participants with HbA1c  7% 425 (60) 26 (58) 
Number (%) of participants with HbA1c  6.5% 283 (40) 19 (42) 
Notes 
* Age at trial initiation 
† Age at interview 
Percentages have been rounded to the nearest whole number 
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Receptiveness towards intensification 
 
Pt45: ‘I was always waking in the morning with it [blood sugar levels] very high […]. So, 
they put me on this one which keeps it steady at night.’ 
 
Pt13: ‘All of a sudden everything went soaring high and I had to up the aspart a great deal 
[…] So then they suggested I go for this […] long acting one overnight […] and that meant 
that I could knock right down the aspart.’ 
 
Managing two types of insulin 
 
Pt36: ‘What (name of nurse) said to me was to take it at bedtime.  Which is fine except 
that I tend to go to bed very late and so we agreed that I would take the insulin at about 
10 o’clock.  Sometimes depending on what’s happening and what I’m doing, sort of 10 
o’clock’s gone past and I haven’t taken it and it might be 11 o’clock or half past 11 before I 
remember to take it.’ 
 
Pt28: ‘In January of o seven they shocked me by saying, “Well, we’re going to have to put 
you onto a different injection” and I thought what, just the different injection? And they said 
“No, no, as well, and by the way, up three times a day.”  So I then realised, five times a 
day!’ 
 
Pt11: ‘And perversely having four injections a day has made it easier to do injections.  It’s 
more routine, it’s more regular and like I say I don't actually think about it.’ 
 
Difficulties with injecting in public 
 
Pt42: ‘It didn’t bother me about using a needle but if people are watching you […] you 
don’t know how they feel about seeing people inject themselves.  So, normally, I try to do 
it in, like a private way.’ 
 
Pt31: ‘I just don’t think I would like to do anything like that (inject) in public, whether I did it 
in my stomach, on my arm or anywhere, no.  No.  They might think I’m a junkie!’ 
 
Pt26: ‘If I go out with anybody I always go and do it (inject) in the toilet.  I won’t ever do it 
outside.’ 
 
Pt1: ‘I used to hide myself away in the toilets and then I used to think, you know, this just 
isn't right. This is silly.  I mean there's more germs in the toilet than there are on, you 
know, a good table cloth.’ 
 
Pt21: ‘With this injection, aspart, you can do it twenty minutes beforehand and then it 
begins to get into the bloodstream or you can do it after your meal but I usually do it 
before because you have a meal out and then you don’t want to dash home.’ 
 
Pt23:  ‘I wouldn’t go out to lunch with them (friends) and in the end I had to tell them why.  
I said, “I can’t.  I have got to have insulin.  And I am not going to go into a toilet”.’ 
Box 1 Participant quotes 
